Drugs / cb-MSCs
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04744116 | Feb 2021 → Mar 2032 expected | acute graft versus host disease, hematopoietic and lymphoid cell neoplasm | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | cb-MSCs | “cord blood tissue-derived mesenchymal stromal cells (cb-MSCs)” NCT04744116 ↗ |
| Modality | Cell therapy | “cord blood tissue-derived mesenchymal stromal cells (cb-MSCs)” NCT04744116 ↗ |
| Route | Intravenous | “Patients also receive lower dose of cb-MSCs IV for up to 60 minutes twice weekly” NCT04744116 ↗ |